# TARS — Tarsus Pharmaceuticals Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** TARS  
**Sources:** 19  
**Published:** 2026-10-04  
**Canonical:** https://app.k3vl4r.com/research/deep-research-tars-tarsus-pharmaceuticals-inc-catalysts-narrative-risk-5952

---

# Tarsus Pharmaceuticals (TARS) — Research Snapshot as of 2026-10-03

## Current Profile
Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company headquartered in Irvine, California, trading on Nasdaq (TARS), focused on eye care. [[4]](https://intickers.com/reports/tars/)[[18]](https://stockanalysis.com/stocks/tars/) As of early October 2026, the stock traded around $73.00, down notably from a September 28 close of $83.21, within a 52-week range of $53.89–$91.53. [[5]](https://www.rttnews.com/3688615/tarsus-pharmaceuticals-completes-alkeus-acquisition-adds-phase-3-stargardt-disease-program.aspx)[[17]](https://www.marketbeat.com/stocks/NASDAQ/TARS/)[[18]](https://stockanalysis.com/stocks/tars/) Shares outstanding stand at roughly 43.88 million. [[4]](https://intickers.com/reports/tars/)[[18]](https://stockanalysis.com/stocks/tars/)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-tars-tarsus-pharmaceuticals-inc-catalysts-narrative-risk-5952 (free to sign up)._